Supriya Lifescience Valuation

Q: What is the Fair Price of SUPRIYA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SUPRIYA (₹703.45) is trading above our estimate of [[fair value]] (₹37.69)

Is SUPRIYA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUPRIYA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SUPRIYA (₹703.45) is trading above our estimate of fair value (₹37.69)

Significantly Below Fair Value: SUPRIYA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUPRIYA?

Key metric: As SUPRIYA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SUPRIYA. This is calculated by dividing SUPRIYA's market cap by their current earnings.
What is SUPRIYA's PE Ratio?
PE Ratio	35.9x
Earnings	₹1.58b
Market Cap	₹55.56b

SUPRIYA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.8x
Enterprise Value/EBITDA	10.4x
PEG Ratio	2.5x

Price to Earnings Ratio vs Peers

How does SUPRIYA's PE Ratio compare to its peers?

The above table shows the PE ratio for SUPRIYA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	42.8x
509079 Gufic Biosciences	48.2x	n/a	₹42.2b
500288 Morepen Laboratories	30.6x	n/a	₹41.6b
524735 Hikal	64.9x	49.2%	₹48.4b
524348 Aarti Drugs	27.5x	31.5%	₹42.3b
SUPRIYA Supriya Lifescience	35.9x	14.3%	₹55.6b

Price-To-Earnings vs Peers: SUPRIYA is good value based on its Price-To-Earnings Ratio (35.9x) compared to the peer average (42.8x).

Price to Earnings Ratio vs Industry

How does SUPRIYA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$72.78m
524652 Ind-Swift	2x	n/a	US$13.52m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: SUPRIYA is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is SUPRIYA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUPRIYA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	35.9x
Fair PE Ratio	32.6x

Price-To-Earnings vs Fair Ratio: SUPRIYA is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the estimated Fair Price-To-Earnings Ratio (32.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

-0.09%

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

14.0%

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

6.1%